Effect of treating severe nasal obstruction on the severity of obstructive sleep apnoea.
An association between mouth breathing during sleep and increased propensity for upper airway collapse is well documented, but the effect of treatment for nasal obstruction on mouth breathing during sleep and simultaneous obstructive sleep apnoea (OSA) severity has not been described previously. A randomised single blind placebo- and sham-controlled crossover study of treatment (topical decongestant and external dilator strip) for nasal obstruction was carried out in 10 patients (nine males; mean+/-SEM 46+/-5 yrs) with nasal obstruction and OSA. All patients had normal acoustic pharyngometry. The effect of treatment on nasal resistance, mouth breathing during sleep and OSA severity was quantified. Treatment of nasal obstruction was associated with a dramatic and sustained reduction in nasal resistance and the oral fraction of ventilation during sleep (mean (95% confidence interval) absolute reduction in oral fraction 30% (12-49)). Improvements in sleep architecture were observed during active treatment, and there was a modest reduction in OSA severity (change in apnoea-hypopnoea index 12 (3-22)). In conclusion, treating nasal obstruction reduced mouth breathing during sleep and obstructive sleep apnoea severity, but did not effectively alleviate obstructive sleep apnoea.
McLean
H A
HA
Dept of Medicine, Queen's University, 102 Stuart Street, Kingston, ON K7L 3N6, Canada.
Urton
A M
AM
Driver
H S
HS
Tan
A K W
AK
Day
A G
AG
Munt
P W
PW
Fitzpatrick
M F
MF
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D018592:Cross-Over Studies; D004106:Dilatation / Q000295:instrumentation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009058:Mouth Breathing / Q000209:etiology / Q000628:therapy; D014663:Nasal Decongestants / Q000008:administration & dosage; D015508:Nasal Obstruction / Q000150:complications* / Q000628:therapy*; D017286:Polysomnography; D020181:Sleep Apnea, Obstructive / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D016896:Treatment Outcome
D014663:Nasal Decongestants